Evaluation of the chemopreventative effects of ALA PDT in patients with multiple actinic keratoses and a history of skin cancer

Journal of Drugs in Dermatology

Volumn 11, Issue 5, 2012, Pages 593-597

  Goldberg, Leonard H ^a,b,c   Landau, Jennifer M ^a   Moody, Megan N ^a   Marquez, Denise ^a   Jih, Ming ^a   Kimyai Asadi, Arash ^a   Friedman, Paul M ^b,c,d   Busch, Angie ^a   Vergilis Kalner, Irene J ^a  

^a DERMSURGERY ASSOCIATES   (United States)

^b HOUSTON METHODIST HOSPITAL   (United States)

^c UNIVERSITY OF TEXAS MEDICAL SCHOOL   (United States)

^d Dermatology and Laser Surgery Center   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMINOLEVULINIC ACID;

ACTINIC KERATOSIS; ADULT; AGED; ARTICLE; CANCER PATIENT; CANCER THERAPY; CARCINOMA IN SITU; CHEMOPROPHYLAXIS; CLINICAL EVALUATION; CONTROLLED STUDY; DRUG EFFECT; FACE; FEMALE; HUMAN; IMMUNOCOMPETENCE; INCUBATION TIME; MAJOR CLINICAL STUDY; MALE; MEDICAL HISTORY; NON MELANOMA SKIN CANCER; OBSERVATIONAL STUDY; PHOTODYNAMIC THERAPY; SCALP; SQUAMOUS CELL CARCINOMA;

ADULT; AGED; AGED, 80 AND OVER; AMINOLEVULINIC ACID; FACIAL NEOPLASMS; FEMALE; FOLLOW-UP STUDIES; HEAD AND NECK NEOPLASMS; HUMANS; KERATOSIS, ACTINIC; MALE; MIDDLE AGED; PHOTOCHEMOTHERAPY; PHOTOSENSITIZING AGENTS; SKIN NEOPLASMS; TIME FACTORS;

EID: 84860893248     PISSN: 15459616     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (29)

1. Moloney FJ, Collins P. Randomized, double-blind, prospective study to compare topical 5-aminolaevulinic acid methylester with topical 5-aminolaevulinic acid photodynamic therapy for extensive scalp actinic keratosis. Br J Dermatol. 2007;157(1):87-91. (Pubitemid 46934264)
2. Nestor MS, Gold MH, Kauvar AN et al. The use of photodynamic therapy in dermatology: results of a consensus conference. J Drugs Dermatol. 2006;5(2):140-54.
3. Tschen EH, Wong DS, Pariser DM, et al. Photodynamic therapy using aminolaevulinic acid for patients with nonhyperkeratotic actinic keratoses of the face and scalp: phase IV multicentre clinical trial with 12-month follow up. Br J Dermatol. 2006;155(6):1262-9. (Pubitemid 44730005)
4. Kalisiak MS, Rao J. Photodynamic therapy for actinic keratoses. Dermatol Clin. 2007;25(1):15-23. (Pubitemid 44780060)
5. Touma D, Yaar M, Whitehead S, Konnikov N, Gilchrest BA. A trial of short incubation, broad-area photodynamic therapy for facial actinic keratoses and diffuse photodamage. Arch Dermatol. 2004;140(1):33-40. (Pubitemid 38090268)
6. Piacquadio DJ, Chen DM, Farber HF et al. Photodynamic therapy with aminolevulinic acid topical solution and visible blue light in the treatment of multiple actinic keratoses of the face and scalp: investigator-blinded, phase 3, multicenter trials. Arch Dermatol. 2004;140(1):41-46. (Pubitemid 38090269)
7. Ormrod D, Jarvis B. Topical aminolevulinic acid HCl photodynamic therapy. Am J Clin Dermatol. 2000;1(2):133-141.
8. Park MY, Sohn S, Lee ES, Kim YC. Photorejuvenation induced by 5-aminolevulinic acid photodynamic therapy in patients with actinic keratosis: a histologic analysis. J Am Acad Dermatol. 2010;62(1):85-95.
9. Smith S, Piacquadio D, Morhenn V, Atkin D, Fitzpatrick R. Short incubation PDT versus 5-FU in treating actinic keratoses. J Drugs Dermatol. 2003;2(6):629-635.
10. Jeffes EW, McCullough JL, Weinstein GD, Kaplan R, Glazer SD, Taylor JR. Photodynamic therapy of actinic keratoses with topical aminolevulinic acid hydrochloride and fluorescent blue light. J Am Acad Dermatol. 2001;45(1):96-104. (Pubitemid 32655701)
11. Jeffes EW, McCullough JL, Weinstein GD, et al. Photodynamic therapy of actinic keratosis with topical 5-aminolevulinic acid. A pilot dose-ranging study. Arch Dermatol. 1997. 133(6):727-32. (Pubitemid 27263706)
12. Xu S, Wang X, Xu W, Xia Y, Zhang C. Evaluation of photodynamic therapy of skin cancers with partial differential alpha-aminolevulinic acid. Chin Med J (Engl). 2002;115(8):1141-1145. (Pubitemid 34947329)
13. Zeitouni NC, Oseroff AR, Shieh S. Photodynamic therapy for nonmelanoma skin cancers. Current review and update. Mol Immunol. 2003;39(17-18):1133-1136. (Pubitemid 36776569)
14. Morton CA, Whitehurst C, McColl JH, Moore JV, MacKie RM. Photodynamic therapy for large or multiple patches of Bowen disease and basal cell carcinoma. Arch Dermatol. 2001;137(3):319-24. (Pubitemid 32240786)
15. Salim A, Leman JA, McColl JH, Chapman R, Morton CA. Randomized comparison of photodynamic therapy with topical 5-fluorouracil in Bowen's disease. Br J Dermatol. 2003;148(3):539-543. (Pubitemid 36461334)
16. Youl PH, Janda M, Aitken JF, Del Mar CB, Whiteman DC, Baade PD. Body site distribution of skin cancer, pre-malignant and common benign pigmented lesions excised in general practice. Br J Dermatol. 2011;165(1):35-43.
17. Braathen LR, Szeimies RM, Basset-Seguin N. Guidelines on the use of photodynamic therapy for nonmelanoma skin cancer: an international consensus. International Society for Photodynamic Therapy in Dermatology, 2005. J Am Acad Dermatol. 2007;56(1):125-143. (Pubitemid 44969292)
18. Fuchs J, Weber S, Kaufmann R. Genotoxic potential of porphyrin type photosensitizers with particular emphasis on 5-aminolevulinic acid: implications for clinical photodynamic therapy. Free Radic Biol Med. 2000;28(4):537-548. (Pubitemid 30136035)
19. Kennedy JC, Pottier RH, Pross DC. Photodynamic therapy with endogenous protoporphyrin IX: basic principles and present clinical experience. J Photochem Photobiol B. 1990;6(1-2):143-148.
20. Gaullier JM, Berg K, Peng Q, et al. Use of 5-aminolevulinic acid esters to improve photodynamic therapy on cells in culture. Cancer Res. 1997;57(8):1481-1486. (Pubitemid 27175564)
21. Uehlinger P, Zellweger M, Wagnières G, Juillerat-Jeanneret L, van den Bergh H, Lange N. 5-Aminolevulinic acid and its derivatives: physical chemical properties and protoporphyrin IX formation in cultured cells. J Photochem Photobiol B. 2000;54(1):72-80. (Pubitemid 30124231)
22. Bunke A, Zerbe O, Schmid H, Burmeister G, Merkle HP, Gander B. Degradation mechanism and stability of 5-aminolevulinic acid. J Pharm Sci. 2000; 89(10):1335-1341.
23. Tsai JC, Chen IH, Wong TW, Lo YL. In vitro/in vivo correlations between transdermal delivery of 5-aminolaevulinic acid and cutaneous protoporphyrin IX accumulation and effect of formulation. Br J Dermatol. 2002;146(5):853-62.
24. Taylor EL, Brown SB. The advantages of aminolevulinic acid photodynamic therapy in dermatology. J Dermatolog Treat. 2002;13(Suppl 1):S3-11.
25. de Graaf YG, Kennedy C, Wolterbeek R, Collen AF, Willemze R, Bouwes Bavinck JN. Photodynamic therapy does not prevent cutaneous squamous-cell carcinoma in organ-transplant recipients: results of a randomized-controlled trial. J Invest Dermatol. 2006;126(3):569-574. (Pubitemid 43255643)
26. Wulf HC, Pavel S, Stender I, Bakker-Wensveen CA. Topical photodynamic therapy for prevention of new skin lesions in renal transplant recipients. Acta Derm Venereol. 2006;86(1):25-28. (Pubitemid 46939784)
27. Wennberg AM, Stenquist B, Stockfleth E, et al. Photodynamic therapy with methyl aminolevulinate for prevention of new skin lesions in transplant recipients: a randomized study. Transplantation. 2008;86(3):423-429.
28. Willey A, Mehta S, Lee PK. Reduction in the incidence of squamous cell carcinoma in solid organ transplant recipients treated with cyclic photodynamic therapy. Dermatol Surg. 2010;36(5):652-8.
29. Apalla Z, Sotiriou E, Chovarda E, Lefaki I, Devliotou-Panagiotidou D, Ioannides D. Skin cancer: preventive photodynamic therapy in patients with face and scalp cancerization. A randomized placebocontrolled study. Br J Dermatol. 2010;162(1):171-175.